In one paragraphArticle in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Liliana SantosFaculty of Medicine, Institute of Pharmacology and Experimental Therapeutics, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0003-2525-9572 Ivanna HrynchakCoimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, Coimbra, Portugal.
José SerenoCoimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, Coimbra, Portugal.
Hugo R S FerreiraFaculty of Medicine, Institute of Pharmacology and Experimental Therapeutics, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.
Magda SilvaCoimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, Coimbra, Portugal.
Alexandra FonsecaCoimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, Coimbra, Portugal.
Rui AlmeidaPathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Paulo TeixeiraPathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Antero J AbrunhosaCoimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, Coimbra, Portugal. antero@pet.uc.pt.ORCID http://orcid.org/0000-0002-4145-854X Célia M F GomesFaculty of Medicine, Institute of Pharmacology and Experimental Therapeutics, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal. cgomes@fmed.uc.pt.ORCID http://orcid.org/0000-0002-7497-4129 Funding
COMPETE2030 FEDER-00749400 Project 17038Fundação para a Ciência e a Tecnologia PD/BDE/150707/2020Fundação para a Ciência e a Tecnologia PTDC/BTM-SAL/4451/2020Fundação para a Ciência e a Tecnologia UIDB/04539/2020Fundação para a Ciência e a Tecnologia UIDP/04539/2020
6 · The paper itselfAbstract
Brain metastases (BrM) are a frequent and devastating complication of HER2-positive (HER2+) breast cancer (BC), affecting up to 30% of patients with metastatic disease. Although trastuzumab has transformed HER2+ BC treatment, its efficacy against BrM remains limited by brain-specific resistance mechanisms and heterogeneous blood-brain barrier (BBB) permeability. Here, we investigated whether HER2-targeted radionuclide therapy (TRT) using the β-emitting radioimmunoconjugate [
Indexed as
Brain NeoplasmsBreast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesLutetiumRadioisotopesTrastuzumabAnimalsCell Line, TumorFemaleHumansMiceRadioimmunotherapyXenograft Model Antitumor AssaysERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLutetiumLutetium-177RadioisotopesTrastuzumabBrain metastasisHER2 + breast cancerLutetium-177Targeted radionuclide therapyTrastuzumab resistance
Identifiers
PMID42734882
PMCPMC13575020
What OpenQuestion holds
Textmetadata
Read underepoch 390